NOTOS: A pivotal study of navtemadlin, a first-in-class mouse double minute 2 inhibitor (MDM2i), in patients (pts) with TP53 wild-type (TP53(WT)) Merkel cell carcinoma (MCC) for whom anti PD-1/L1 therapy has failed.Michael K. K. Wong,Melissa Amber Burgess,Sunandana Chandra,Leslie Anne Fecher,Caroline Gaudy-Marqueste,Ann W. Silk,Glenn J. Hanna,Celeste Lebbe,Gaelle Quereux,Guilherme Rabinowits,Dirk Schadendorf,Caroline Dutriaux,Carola Berking, Juan Martin Liberal,Paolo Antonio Ascierto, Emily Houlihan, Kim Steinmann, Tiffanie Chan, Wayne P. Rothbaum,Ciara Marie KellyJOURNAL OF CLINICAL ONCOLOGY（2023）引用 0|浏览25暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
